? ? Lung cancer is a major health concern with a very high mortality rate, afflicting approximately 170,000 people each year in the United States. Because most lung cancer patients are diagnosed at a late stage of the disease and available therapies are usually ineffective, the prognosis is very poor for most lung cancer patients. Theoretically, blockage of the multiple-step process of the progression from preinvasive disease to malignancy will reduce the incidence of advanced lung cancer. Therefore, development of effective prevention agents against lung cancer is critical for reducing mortality. In this study, we will focus on the flavonoid luteolin (3',4',5,7-tetrahydroxyflavone) as a potential lung cancer chemoprevention agent. Our preliminary studies demonstrate that the flavonoid luteolin selectively kills transformed but not normal lung cells and that reactive oxygen species (ROS) accumulation is essential for the luteolin-induced cytotoxicity in lung cancer cells. To establish the basis of future studies on the activity and mechanism of luteolin in lung cancer prevention, we plan to determine the underlying mechanism by which luteolin kills lung cancer cells in an in vitro cell culture system. The hypothesis driving this application is that luteolin-induced ROS mediates activation of c-Jun N- terminal kinase (JNK), which subsequently triggers activation of apoptosis pathways in transformed lung cells. This activation of apoptosis contributes to the chemopreventive activity of luteolin against lung cancer. We will test this hypothesis in the following specific aims: 1) to determine the mechanism by which luteolin induces ROS accumulation in lung cancer cells, 2) to determine the mechanism by which luteolin induces apoptosis in lung cancer cells, and 3) to determine the mechanism of selective cytotoxicity of luteolin in lung cancer cells. The success of this project would lead to development of future studies in animals and humans to test the preventive activity and mechanism of luteolin against lung cancer in vivo, which may lead to the clinical application of luteolin for human lung cancer prevention. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Research Grants (R03)
Project #
1R03CA125796-01A1
Application #
7319665
Study Section
Special Emphasis Panel (ZCA1-SRRB-F (M1))
Program Officer
Perloff, Marjorie
Project Start
2007-06-15
Project End
2009-05-31
Budget Start
2007-06-15
Budget End
2008-05-31
Support Year
1
Fiscal Year
2007
Total Cost
$102,500
Indirect Cost
Name
Lovelace Biomedical & Environmental Research
Department
Type
DUNS #
045911138
City
Albuquerque
State
NM
Country
United States
Zip Code
87108
Bai, Lang; Xu, Xiuling; Wang, Qiong et al. (2012) A superoxide-mediated mitogen-activated protein kinase phosphatase-1 degradation and c-Jun NH(2)-terminal kinase activation pathway for luteolin-induced lung cancer cytotoxicity. Mol Pharmacol 81:549-55
Chen, Wenjie; Bai, Lang; Wang, Xia et al. (2010) Acquired activation of the Akt/cyclooxygenase-2/Mcl-1 pathway renders lung cancer cells resistant to apoptosis. Mol Pharmacol 77:416-23
Lin, Yong; Bai, Lang; Chen, Wenjie et al. (2010) The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets 14:45-55
Bai, Lang; Chen, Wenshu; Chen, Wenjie et al. (2009) IKKbeta-mediated nuclear factor-kappaB activation attenuates smac mimetic-induced apoptosis in cancer cells. Mol Cancer Ther 8:1636-45
Bai, Lang; Chen, Wenjie; Wang, Xia et al. (2009) Attenuating Smac mimetic compound 3-induced NF-kappaB activation by luteolin leads to synergistic cytotoxicity in cancer cells. J Cell Biochem 108:1125-31
Wang, Xia; Chen, Wenshu; Zeng, Weihua et al. (2008) Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Mol Cancer Ther 7:1156-63
Chen, Wenshu; Wang, Xia; Bai, Lang et al. (2008) Blockage of NF-kappaB by IKKbeta- or RelA-siRNA rather than the NF-kappaB super-suppressor IkappaBalpha mutant potentiates adriamycin-induced cytotoxicity in lung cancer cells. J Cell Biochem 105:554-61
Lin, Yong; Shi, Ranxin; Wang, Xia et al. (2008) Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets 8:634-46
Wang, Xia; Lin, Yong (2008) Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin 29:1275-88
Chen, Wenshu; Wang, Xia; Zhuang, Jianguo et al. (2007) Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells. Carcinogenesis 28:2114-21